PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict
The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and...To view the full article, register now.
Already a subscriber? Click here to view full article